That secretive ARCH biotech with two antibodies from MorphoSys? It’s now got $120M

In June, HI-Bio, short for Human Immunology Biosciences, licensed two candidates from German biotech MorphoSys — felzartamab for two autoantibody liver diseases, and HIB210, which goes after the C5a receptor, the same target that new Amgen subsidiary ChemoCentryx’s drug won approval on last year. HI-Bio holds the rights on the...

Click to view original post